Bicycle Therapeutics plc reported its financial results for the first quarter of 2025, revealing a net loss of $60.8 million compared to a net loss of $26.6 million in the same period the previous year. The company also noted that its cash and cash equivalents stood at $793.0 million as of March 31, 2025, down from $879.5 million as of December 31, 2024. This decrease is attributed mainly to operational cash usage, including increased expenses related to clinical program activities. Significant business progress was also highlighted, with multiple abstracts accepted for presentation at the 2025 ASCO and AACR annual meetings. Bicycle Therapeutics continues to advance its oncology pipeline, with the Phase 1/2 Duravelo-3 trial for zelenectide pevedotin in NECTIN4-amplified breast cancer now open and actively recruiting patients. Additionally, the company has bolstered its business and clinical expertise through strategic appointments to its Board of Directors, Clinical Advisory Board, and management team.